European Commission Initiative on Breast Cancer (ECIBC): Plenary 2016 by BRAMESFELD ANKE et al.
European Commission
Initiative on Breast Cancer 
(ECIBC):  Plenary 2016 
When Science and Policy collaborate for Health
Bramesfeld, A; Ambrosio, M; Bocchi, G;  
Deandrea S; Dimitrova, N; Saz-Parkinson, Z; 
Ulutürk Tekin, A; Lerda, D.
Joint 
Research
Centre
This publication is a Conference report by the Joint Research Centre (JRC), the European 
Commission’s science and knowledge service. It aims to provide evidence-based scientific 
support to the European policymaking process. The scientific output expressed does not 
imply a policy position of the European Commission. Neither the European Commission 
nor any person acting on behalf of the Commission is responsible for the use that might 
be made of this publication.
Contact information 
Name: Health in Society Unit
Address: Joint Research Centre, Directorate F-Health, Consumers and Reference Materials 
Via Enrico Fermi 2749, TP 127, 21027 Ispra (VA), Italy
Email: jrc-cancer-policy-support@ec.europa.eu
Tel.: +39 0332 78 6201  
Web: ecibc.jrc.ec.europa.eu 
JRC Science Hub 
https://ec.europa.eu/jrc 
JRC 106915
EUR 28683 EN
PDF ISBN 978-92-79-70521-2 ISSN 1831-9424 doi:10.2760/87978
Luxembourg: Publications Office of the European Union, 2017
© European Union, 2017
The reuse of the document is authorised, provided the source is acknowledged and the 
original meaning or message of the texts are not distorted. The European Commission 
shall not be held liable for any consequences stemming from the reuse.
Front cover image © Isaac Lane Koval/Corbis/VCG and © European Union 
|  3
Table of contents
Acknowledgements 5
1. Introduction 8
2.  Day 1 – Science for policy development 11
2.1 Welcome & Opening 11
2.1.1 Welcome note (Charlina Vitcheva, JRC) 11
2.1.2  The patient’s perspective on the ECIBC (Marja Aarnipuro, Apu 
magazine, Finland) 12
2.1.3  Launch of the first set of European Breast Guidelines 
Recommendations (Elke Anklam, JRC) 13
2.2 Keynote 14
2.2.1  What kind of science is successful in supporting policy 
development – the scientist’s perspective (Josep Figueras, 
European Observatory on Health Systems & Policies) 14
2.3  News and updates from the ECIBC projects (moderated 
by Elke Anklam, JRC, and Zofija Mazej Kukovič, Slovenian policymaker) 15
2.3.1 Session introduction (Zofija Mazij Kukovič) 16
2.3.2  Status of the development of the European Quality Assurance 
scheme for Breast Cancer Services (Robert Mansel, QASDG chair) 
2.3.3  Status of the development of the European guidelines 
for breast cancer screening and diagnosis (Chris de Wolf 
and Holger Schünemann, GDG co-chairs) 18
2.3.4  Status of the development of the Guidelines Platform 
(Donata Lerda, JRC) 20
2.3.5  Training on digital mammography: a European approach 
(Aslı Ulutürk, JRC) 20
2.3.6 Monitoring the impact of the ECIBC (Nadya Dimitrova, JRC) 22
2.3.7 ECIBC video presentation (Ciarán Nicholl, JRC) 22
2.4  Making comparable performance assessment possible in Europe 
using the accreditation legal framework (moderated by Jane 
Beaumont, Accreditation Advisor, and Marc van den Buckle,  
Scientific Institute of Public Health, Brussels) 23
2.4.1  What is the accreditation legal framework? What are 
17
|  4
its benefits and shortcomings? (Ed Wieles, Dutch Accreditation 
Council, the Netherlands) 23
2.4.2  The role of the accreditation legal framework in the European 
QA scheme (Silvia Deandrea, JRC & Aliki Stathopoulou, 
QASDG member) 24
2.4.3  Experience with using ISO 15189 as an option for accrediting 
pathology laboratories (Marco Pradella, Local Health Authority,
Asolo, Italy) 25
2.4.4  Experiences with implementing ISO 15189 (Katrien 
Gruenberg, Radboud University Medical Center (UMC), 
Nijmegen, the Netherlands) 26
3.  Day 2 – Policy for science implementation 27
3.1  Country presentations: Breast cancer services in European 
countries and the European QA scheme: country profiles  
(moderated by Tit Albrecht, National Institute of Public Health, 
Slovenia & Stefan Schreck, DG SANTE) 28
3.1.1 Scotland (Hillary Dobson, NHS Scotland) 28
3.1.2  The Netherlands (Ruud Pijnappel, UMC Utrecht, on behalf 
of Sabine Siesling, University of Twente) 29
3.1.3 Romania (Luciana Neamțiu, on behalf of Florian Nicula, 
Romanian programme for cancer prevention and control) 29
3.2 Country tables (Donata Lerda, JRC) 32
3.2.1 European Breast Guidelines 33
3.2.2 European QA scheme 34
3.3 Round table discussion 35
3.4  Conclusions (Alojz Peterle, President of MEPs Against Cancer 
(MACs), European Parliament) 37
4. Evaluation 38
5. Conclusion 39
6. Annexes 41
Participants 44
References 48
|  5
Acknowledgements 
We would like to thank the country delegates, experts, patient representatives and all 
other participants who attended the 2016 ECIBC Plenary for their engagement. Thanks 
to their input, the 2016 ECIBC Plenary succeeded in not only informing stakeholders but, 
most importantly, providing the JRC with valuable information, feedback and suggestions 
for further developing the initiative. Beyond this, we wish to thank all presenters, as 
well as the round table participants, for their well-prepared, thoughtful and inspiring 
contributions that shaped and provided anchor points for the discussions. 
As the ECIBC is coordinated by the JRC and supervised by DG SANTE, continued support 
from the JRC hierarchy and DG SANTE colleagues is essential to its success and should 
be acknowledged. 
Finally, we wish to thank Brigitte Westritschnig and Chiara Margagliano for their invalu-
able support in the organisation of ECIBC Plenaries, and Nicola Davenport from RETELL 
for drafting this report and assisting in its finalisation.
Authors
Bramesfeld, Anke; Ambrosio, Massimo; Bocchi, Giulia; Deandrea, Silvia; Dimitrova, Nadya; 
Saz-Parkinson, Zuleika; Ulutürk Tekin, Asli; Lerda, Donata. 
|  6
Abstract 
The European Commission Initiative on Breast Cancer (ECIBC) Plenaries are an opportunity 
to inform representatives from the 28 EU Member States and 7 other countries 
participating in the ECIBC, as well as patients and other stakeholders, policymakers, and 
the scientific and health policy communities, about the aims, activities and achievements 
of the ECIBC. They also provide a platform for the exchange of ideas, feedback and input 
into the ECIBC.
The 2016 ECIBC Plenary, entitled “When science and policy collaborate for health”, took 
place on 24-25 November in Varese, Italy. Its main focus was the implementation of both 
the voluntary European Quality Assurance scheme for Breast Cancer Services (European QA 
scheme) and the European guidelines for breast cancer screening and diagnosis (European 
Breast Guidelines). In this context, the first concrete results were presented, with the launch 
of the first four European Breast Guidelines recommendations on screening. 
The first day of the Plenary was dedicated to the JRC informing the audience about 
the various tools that ECIBC is developing. The second day instead, gave the floor to 
the audience, who informed the JRC of their views in terms of the challenges and 
opportunities related to implementing the ECIBC in the respective European countries. 
The event opened with welcome speeches from the European Commission’s Joint Research 
Centre (JRC), a moving presentation from a breast cancer survivor and reflections on how 
to ensure science makes its way into policy. The JRC and ECIBC working group members 
then brought the audience up to date with progress on the European QA scheme, the 
European Breast Guidelines, as well as the Guidelines Platform, the template for training 
on digital mammography, as well as about how ECIBC plans to monitor its impact. 
Participants also received in-depth explanations of the accreditation framework selected 
for the European QA scheme, as well as two countries’ experiences of using the ISO 
15189 standard for accreditation, which is foreseen for the European QA scheme.
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The second day saw a focus on the individual countries represented at the Plenary. 
Presentations assessed how the European QA scheme could potentially fit into three 
different health systems (Scotland, the Netherlands, Romania), while a special break-
out session gave national representatives from the 27 countries present (out of the 
35 countries participating in the ECIBC) the chance to discuss implementation of the 
European Breast Guidelines and the European QA scheme themselves. The results, 
collected through questionnaires, fed into a roundtable debate on what needs to be done 
at European and national level to ensure ECIBC implementation.
The meeting was closed by Member of the European Parliament and President of MEPs 
Against Cancer (MACs), Alojz Peterle.
An evaluation of the event revealed that the third ECIBC Plenary met its aims to inform 
stakeholders: all responding participants felt that the event succeeded in providing a 
comprehensive overview of how the ECIBC is progressing, and what the challenges are. 
Discussions also provided the JRC with valuable information and feedback. 
The fourth ECIBC Plenary will take place once the results from piloting the European QA 
scheme are available.  
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Introduction
In response to the Council of the European Union’s conclusions on reducing the burden 
of cancer, the European Commission (EC) founded the European Commission Initiative on 
Breast Cancer (ECIBC) (ecibc.jrc.ec.europa.eu). The ECIBC aims at ensuring and improving 
the quality of breast cancer services, and through this, at improving health and 
reducing health inequalities in Europe. To attain these aims, the ECIBC is developing the 
following tools:
• the European guidelines for breast cancer screening and diagnosis
(European Breast Guidelines) which are based on the latest knowledge and
evidence;
• a platform for breast cancer guidelines (Guidelines Platform) that hosts
current high quality and evidence-based recommendations on breast cancer
treatment, rehabilitation follow-up and end-of-life care;
• the voluntary European Quality Assurance scheme for Breast Cancer
Services (European QA scheme), which is based on the EU legislative
framework on accreditation, and evidence derived from the European Breast
Guidelines and the Guidelines Platform;
• a European template for training on digital mammography (DM training),
directed at health professionals involved in screening programmes, including the
essential requirements for those wishing to adhere to the European QA scheme;
• a long-term web hub hosting all the deliverables (information, output
and tools) developed within the ECIBC, making it the communication interface
with stakeholders and including, whenever feasible, stakeholders’ input on
desirable features.
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The ECIBC is coordinated by the Joint Research Centre (JRC), which is responsible for its 
scientific and technical content and deliverables, while the EC’s Directorate General for 
Health and Food Safety (DG SANTE) is the overall responsible for EU cancer policies. 
The ECIBC organises Plenaries to inform EU Member States and other participating 
countries, patients and other stakeholders, such as national accreditation bodies, 
associations of professionals, policy makers and the scientific and health-policy 
communities, about the aims, activities, and achievements of the ECIBC; in particular 
the state of development of the various tools. At the same time, the ECIBC uses the 
plenaries to collect feedback and input on its activities. Finally, the plenaries are intended 
to induce ECIBC implementation by informing, engaging and linking policy makers and 
stakeholders active in breast cancer care with the ECIBC initiatives.
The first ECIBC Plenary in 2013 launched the initiative and collected input from concerned 
countries and professionals on how to design it. The second, in 2015, marked the uptake 
of the actual development work. This is supported by two working groups comprising 
experts and representatives of patients and citizens: the Guidelines Development Group 
(GDG) and the Quality Assurance Scheme Development Group (QASDG). The third ECIBC 
Plenary in 2016, which is the subject of this report, addressed the future  implementation 
of both the European Breast Guidelines and the European QA scheme. 
The first y ear o f d evelopment w ork s ucceeded i n fi nalising th e sc ope fo r bo th th e 
European Breast Guidelines and the European QA scheme, defining and publishing the 
methodology to be used by both working groups, and finally launching the fi rst four 
guidelines recommendations. The Plenary drew attention to the feasibility of implementing 
the European Breast Guidelines, and in particular the European QA scheme, in each of 
the 35 countries involved in the ECIBC. Its title, “When science and policy collaborate for 
health”, conveys the exact challenge faced by the ECIBC: not only the development of 
scientifically sound tools, but also how to develop and disseminate them in such a way 
that they will be of added value to health services and systems in European countries 
and be implemented there. 
The first day of the Plenary was dedicated to the JRC informing country 
representatives and stakeholders about the various tools that ECIBC is developing. 
The second day instead, gave the floor to country representatives and 
stakeholders, who were invited to inform the JRC of their views on the challenges 
and opportunities related to implementing ECIBC in the respective European countries.
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The first day of the Plenary focused on “Science for policy development”. It looked at 
the conditions required to transfer science into policy and informed participants of 
the current state of development of the ECIBC tools. As the European QA scheme 
will be operating within the EU legislative framework on accreditation, the Plenary 
dedicated the afternoon of the first day to exploring in-depth the implications that this 
has for implementation in individual countries, and for breast cancer services and related 
pathology laboratories in particular. 
The second day focused on “Policy for science implementation”, and looked at each country 
separately in terms of facilitators for — and obstacles to — implementing the guidelines 
and the QA scheme. The JRC was particularly keen to learn about organisations, bodies 
and persons which could be approached in each country to facilitate discussions and 
overcome obstacles. 
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2.  Day 1 — Science for policy
development
2.1 Welcome & Opening
The Welcome & Opening session reminded participants of the aims and implications of 
the ECIBC from an EU perspective, as well as the perspective of the ultimate beneficiaries 
of the ECIBC: patients and citizens. In this context, the first concrete outcome of the 
ECIBC, the first recommendations from the European Breast Guidelines, were launched. 
2.1.1 Welcome note (Charlina Vitcheva, JRC)
The subject of the Plenary — science and policy collaborating for health — is close 
to the JRC’s heart and mission, Vitcheva explained. The JRC’s mission is to provide the 
evidence and the scientific facts and figures that can support policymaking, so as to 
ensure future policies are credible and robust. 
The ageing population has meant a shift in the causes of mortality, with cancer now 
responsible for an increasing share of deaths. In 12 out of 28 EU countries, cancer is the 
leading cause of death. The European Commission is therefore stepping up its efforts 
to tackle the disease. “We need to examine what we can do better, to improve 
healthcare, to collect the right information to underpin policies, and to improve 
management of system around cancer services,” said Vitcheva.
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Within the ECIBC, the JRC and DG SANTE are joining forces to improve cancer 
detection and care. Vitcheva thanked all involved, including experts, stakeholders, 
patient organisations, businesses, and colleagues from both the JRC and DG SANTE. She 
closed by calling on all present to continue being as ambitious as they have been to date.
2.1.2  The patient’s perspective on the ECIBC (Marja Aarnipuro, Apu 
magazine, Finland)
Aarnipuro’s presentation was a reminder to all those present of the importance of 
tackling the quality of breast cancer care, in particular in respect to informing 
patients. She spoke of three periods of fear she experienced when being diagnosed with 
cancer in 2009. The first period while waiting one week for her biopsy results ; she even 
planned her funeral, thought about how her children would cope without their mother, 
and convinced herself she would die within weeks or months. “This is because I didn’t 
know enough.”
Although the diagnosis was given over the phone, it was a relief, because Aarnipuro 
finally had facts. It was time for action. “Ignorance increases pain, not knowledge.”
Aarnipuro experienced the second period of fear during the two weeks after her operation 
until she found out that her cancer was not metastatic; she described these weeks as 
the longest of her life. Appealing to those present, Aarnipuro asked for practitioners to 
provide facts as soon as possible and to shorten the wait for initial biopsy results, and 
those of follow-up pathology tests.
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The third period came when the treatment was over, and “the cancer clinic door closed 
behind me”. Aarnipuro felt she was now expected to be normal again, instead she began 
noticing symptoms, although nothing could be found, and felt very alone. Each time she 
waited a week or so before going to her doctor, scared of what tests might find. After living 
in fear for two years, Aarnipuro gradually started to trust life again. She pointed out that 
there has been great progress in many fields in Finland since her diagnosis and every 
patient now fills in a questionnaire and is provided with psychosocial help if necessary. A 
breast cancer treatment pathway is also available online, while an e-health application, 
currently undergoing testing, allows a patient to report any symptom whenever she 
wants, even in the middle of the night. If the symptom seems severe, a nurse will contact 
her the next working day.
2.1.3  Launch of the first set of European Breast Guidelines 
Recommendations (Elke Anklam, JRC)
These first four recommendations were published around a year after the GDG took up 
its work. The recommendations are published on the ECIBC web hub; different 
entry points for women, professionals and policymakers ensure that each 
target group finds the information it needs. The recommendations are presented 
with additional information on the group’s confidence in the evidence on which the 
recommendations are based. In summary they suggest:
• No implementation of mammography screening for asymptomatic women aged 
40 to 44, with an average risk of breast cancer (Conditional recommendation).
• Organised mammography screening programmes for asymptomatic
women aged 45 to 49 with an average risk of breast cancer (Conditional
recommendation).
• Organised mammography screening programmes for asymptomatic women
aged 50 to 69 with an average risk of breast cancer (strong recommendation).
• Organised mammography screening programmes for asymptomatic
women aged 70 to 74 with an average risk of breast cancer (Conditional
recommendation).
“This is an example for European added value” Anklam said, “common recommendations 
for all women based on evidence. Let’s go on, let’s proceed!”
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2.2 Keynote
2.2.1  What kind of science is successful in supporting policy 
development – the scientist’s perspective (Josep Figueras, 
European Observatory on Health Systems & Policies)
Neither the European Breast Guidelines 
recommendations nor the European QA 
scheme will be of value if not taken up and 
used by European countries and breast 
centres. However, the transfer of scientific 
results into policy and clinical implementation 
is one of the major challenges faced by 
many scientific initiatives. How to tackle this 
challenge and what to consider when drafting 
an implementation strategy were outlined in a 
keynote presentation that tied together Day 1 
on science development and Day 2 on policy 
implementation.
Figueras started by asking why some countries 
and/or sectors implement guidelines, and 
others not. Increasing uptake relies heavily 
on understanding the policy decision-
making process, but the process is rarely clear-cut, and never a simple, linear process. 
Relevant factors include politics, equity, ethics, consumer and industry lobbying, and the 
media. It is also important to remember who the key actors are — in this instance, they 
include insurance companies and regulators. 
Psychology is also important. People tend to use heuristics or mental shortcuts when 
faced with complex choices. They are also inclined to look at results that confirm what 
they want to do. Sunk costs bias also plays a role — it can be difficult to change course 
after investing in a particular approach. So there is a tendency to look for the least 
complex solution, not one based on evidence.
Figueras recommended targeting networks and working with opinion leaders, 
while ensuring that knowledge-brokering organisations are invited to meetings, 
and not only the “usual suspects”. 
Context is also key. This can include political structures (devolved or not) and administrative 
arrangements, health system characteristics, timelines (there are moments when it 
is easier to introduce a new initiative), perceived severity of the problem addressed, 
resource availability and cultural proximity.
Finally, the tools used to encourage implementation are also important. From 
benchmarking to naming and shaming, auditing, legislation and regulation, incentives 
and penalties — each can have a role to play.
2.3  News and updates from the ECIBC projects (moderated 
by Elke Anklam, JRC, and Zofija Mazej Kukovič, Slovenian 
policymaker)
To update the audience on the current status of ECIBC projects as a baseline for discussing 
implementation, the chairs of the GDG and QASDG presented their groups’ work 
and achievements during the 11 months since the previous Plenary in 2015. 
Achievements included finalising the scope for the European Breast Guidelines and 
the European QA scheme, collecting feedback via a public consultation with stakeholders 
and countries, and having them approved by the respective working group. In addition, 
both working groups defined their methodological approach and began development work: 
the QASDG started to identify requirements and indicators to be included in the 
European QA scheme and the GDG developed the first guidelines recommendations. 
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JRC colleagues also informed Plenary participants about further tools under development 
or completed, including an ECIBC video clip. 
But before the session started, Zofija Mazij Kukovič from Slovenia, who was health minister 
at the time of the Slovenian EU council presidency when the Council of the European Union’s 
conclusions on reducing the burden of cancer were adopted, spoke of events at that time. 
It was thanks to her intervention that the council conclusions invited the Commission to 
“explore the potential for the development of voluntary European accreditation schemes 
for cancer screening and appropriate follow-up of lesions detected by screening, such as a 
European pilot accreditation scheme for breast cancer screening and follow-up based on 
the European guidelines for quality assurance in breast cancer screening and diagnosis.”
2.3.1 Session introduction (Zofija Mazij Kukovič)
When Slovenia selected cancer as a health 
priority for its EU Council Presidency in the 
first half of 2008, one in three EU citizens was 
suffering from the disease. The decision led to 
a 2008 European Parliament Resolution 
on combatting cancer that called for 
improved EU collaboration and an end 
to fragmentation. This has led to a more 
integrated strategy, and probably saved lives 
of cancer sufferers, said Kukovič. 
The ministerial meeting had agreed on a 
recipe for a common approach, but it was 
unclear how to balance different health 
budgets, insurance systems, education 
systems, levels of expertise for screening, 
diagnosis and treatment, and psychological 
and social support. The Member States were 
invited to find ways of working together, and they are now doing so within the ECIBC. 
“It’s very rare in politics that you see such progress in eight years” said Kukovič. 
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2.3.2  Status of the development of the European quality assurance 
scheme for breast cancer services (Robert Mansel, QASDG 
chair)
Mansel began with a reference to Marja Aarnipuro’s speech that he saw as evidence 
of the need for the ECIBC: change is needed, he said. Patients should not receive their 
diagnosis over the telephone, for example, as she had experienced. 
Updating listeners on the progress that the Quality Assurance Scheme Development Group 
(QASDG) is making in developing the European Quality Assurance scheme for Breast Cancer 
Services (European QA scheme), Mansel explained that it will address the entire 
breast cancer pathway and will have a modular structure to accommodate the fact 
that not every cancer centre provides care at every step of the pathway. 
The QASDG’s work began back with a public call for feedback on the scope of the 
European QA scheme that addressed the ECIBC National Contacts, national accreditation 
bodies, healthcare organisations, professional organisations and individuals. This call 
for feedback confirmed that the modular approach of the European QA scheme 
was applicable to the healthcare system of each country, as was the breast 
cancer treatment pathway published on the ECIBC web hub. The ISO standards proposed 
were also considered acceptable.
Respondents to the call for feedback raised two concerns: one on the applicability of 
ISO 15189 as an accreditation standard for pathology laboratories in Germany, and the 
other on a lack of detailed information on the methodology used for the selection of 
requirements and indicators. These concerns are respectively taken up in the report on the 
call for feedback on the scope, and in a methodology document that can be found on the 
ECIBC web hub.
To date, the QASDG has consented on a methodology for identifying requirements 
and indicators using Delphi rounds and all QASDG members have been trained for 
participating. The QASDG has begun identifying requirements/indicators for surgery and 
the organisational structure of breast centres. However to complete this process, the 
group awaits evidence from the European Breast Guidelines and the Guidelines Platform 
that is currently under construction; the set of requirements/indicators for the European 
QA scheme is expected to be finalised by 2018.
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For the accreditation of conformity assessment bodies, a first draft of the 
scheme owner requirements is under development. For accreditation of imaging 
services, medical and pathology laboratories, work is ongoing to identify testing and 
examination activities that fall under the scope of accreditation (to be ready by mid-
2017), as well as the reference documents needed to set performance levels (to be 
ready by mid-2018).
Finally, to assess breast centres, data will be needed. IT solutions are under development 
to support breast centres in aggregating data for requirements and indicators in a 
way that is reliable and sound while respecting data protection requirements. The European 
QA scheme will be piloted from 2018 in breast centres around Europe.
2.3.3  Status of the development of the European guidelines 
for breast cancer screening and diagnosis (Chris de Wolf 
and Holger Schünemann, GDG co-chairs)
As with the QASDG, discussions to determine the scope and purpose of the European 
Breast Guidelines, as well as the target audience, preceded work by the GDG. A public call 
for feedback in 2016 resulted in 81 responses from organisations and individuals. The 
final scope, which included modifications in line with feedback received, will be available 
on the ECIBC web hub in 2017, along with the feedback report.
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The working group is developing recommendations for screening and diagnosis 
using GRADE methodology. This means that they formulate questions to the evidence 
using a structured format, generally called “PICO”, which stands for Population under study 
(for example women of certain age); Intervention (for example a medical examination); 
Comparator (for example an alternative medical examination); and Outcomes (results). 
The evidence is searched for using existing systematic reviews or by conducting new 
ones. In this phase, the GDG rates the overall quality of the collected evidence (resulting 
from a combined rating of the quality of evidence for each outcome and the quality of 
evidence for each recommendation across all outcomes). It is then discussed and the 
quality level of evidence is agreed within the GDG.
In order to go then from the evidence to the recommendation, the GDG uses evidence-to-
decision frameworks (Etds). These take into account the magnitude of the problem, 
the balance of benefits and harms of the intervention, resources needed, cost-
effectiveness, peoples’values and preferences in regard to  the main outcomes, 
impact on health equity, acceptability of the intervention and feasibility of 
implementing the intervention. According to this assessment, the GDG reaches a 
consensus, or votes if they cannot agree, on the criteria that influence a recommendation 
or decision. Agreement is reached on the direction of each recommendation (in 
favour or against the intervention) and its strength (strong or conditional), leading to 
recommendations such as the four launched at the Plenary. Potential conflicts of 
interest are managed strictly on a question by question basis.
The development of recommendations, published online, in versions tailored to patients/
citizens, healthcare professionals and policy makers, and translated into all EU languages, 
will continue until 2018.
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2.3.4  Status of the development of the Guidelines Platform 
(Donata Lerda, JRC)
While the European Breast Guidelines provide the evidence for screening and diagnosis 
used by the European QA Scheme as a reference, evidence for all treatment-related 
processes comes from the Guidelines Platform — a collection of current evidence-
based guidelines on breast cancer care.
An initial search sought guidelines documents published after 2006 and relevant for all 
treatment-related processes covered by the pathway. A total of 2 551 publicly available 
records were found, of which 230 were considered eligible. A survey was launched to 
identify non-public guidelines, leading to an additional 50 eligible ones.
A contractor is now evaluating the evidence base of all the guidelines collected and 
scoring them according to AGREE II domains. Only guidelines that score above a set 
threshold will be included in the platform. The contractor is blind in respect to this 
threshold, which the JRC will set based on the evidence and expert opinions of two other 
independent contractors. Maximum independence is thus guaranteed.   
Recommendations included in the Guidelines Platform will be presented, wherever 
possible, in the same format as those of the European Breast Guidelines. 
2.3.5  Training on digital mammography: a European approach (Aslı 
Ulutürk, JRC)
Well trained professionals are needed to ensure high quality breast cancer care and 
crucial in a population-based intervention like screening. The JRC is therefore developing 
a template for training on digital breast cancer screening. The template is intended 
for radiologists and radiographers/radiation technologists, and will cover 
minimum training requirements.
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The initiative has now moved into the development phase from the preparatory research 
phase. The four key research activities performed include:
1.  A Europe-wide survey on training requirements, training practice, licensing practices,
continued professional development, audit processes. Of the replies received to
this survey by mid-November, two thirds said that screening-specific training was
mandatory in their organisation, and one third said that continued professional
development was mandatory.
2.  A systematic search for existing templates for radiologist and radiographer/radiation
technologist training. This involved searching databases and websites of professional
organisations, health authorities and entities providing screening.
3. A call for training templates.
4.  A search for existing e-modules for training, diploma programmes, minimum
requirements etc.
The template for the European training for radiologists and radiographers/radiation 
technologists will be based on results gathered by the survey and will respect countries’ 
existing frameworks. 
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2.3.6 Monitoring the impact of the ECIBC (Nadya Dimitrova, JRC) 
Examining the impact of the ECIBC, and in particular its two main outcomes, the European 
QA scheme and the European Breast Guidelines, will be of utmost importance. To do 
this, it is necessary to first define indicators that will show the ECIBC’s impact at 
different levels e.g. populations, services, patients/citizens, and then to collect relevant 
data for these indicators. 
The JRC is currently considering various scenarios for evaluating the ECIBC’s impact:
• comparing indicators before and after implementation in the same population/
service;
• comparing services and populations implementing the guidelines and QA
scheme with those not doing so;
• a modelling approach.
All three approaches could be used in a complementary fashion or separately, depending 
on the data available. The next step will be to consult experts and stakeholders before 
developing a roadmap to a monitoring and evaluation plan.
2.3.7 ECIBC video presentation (Ciarán Nicholl, JRC) 
A video introducing the ECIBC was developed in-house within the JRC and presents the 
inclusive, patient-centric and multi-disciplinary nature of the ECIBC. Under the motto 
“ECIBC is Europe that cares”, the video outlines the benefits expected to come out of 
the ECIBC for women: guaranteed quality without inequality and empowered women.  
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2.4  Making comparable performance assessment possible in 
Europe using the accreditation legal framework (moderated 
by Jane Beaumont, Accreditation Advisor, and Marc van den 
Buckle, Scientific Institute of Public Health, Brussels)
The European QA Scheme will be run within the EU’s legal framework for accreditation. 
This session was intended to explore more in depth, in particular for those participants who have 
not worked within the accreditation legal framework previously, what accreditation means. 
The session therefore began with an explanation of the legal basis and of the infrastructure 
provided, before moving on to how it would impact the European QA Scheme, and ending with 
experiences in two countries about its usability for accrediting pathology laboratories. This 
showed the advantages that accreditation under the legal framework offers, such as providing 
a trans-European harmonised benchmarking and auditing system, but also its limitations, due 
to a prevalent focus of the legal framework on processes rather than on outcomes. 
2.4.1  What is the accreditation legal framework? What are its 
benefits and shortcomings? (Ed Wieles, Dutch Accreditation 
Council, the Netherlands)
Prior to 2010, individual countries had different structures for accreditation, and both 
private and public accreditation bodies — and sometimes multiple bodies — were 
active. Some had no legal status. Bodies were usually allowed to accredit outside their 
own country, and there was no formal requirement for peer evaluations. There was also 
no formal recognition of the European co-operation for Accreditation (EA).
In 2010, EC Regulation No 765/2008 on accreditation and market surveillance was 
implemented. It requires each accreditation body to have a mandate as a public 
authority and limits national accreditation bodies to one per EU Member State. It 
prohibits profit distribution to shareholders and competition (no cross-border application 
unless there are exceptional circumstances), and places emphasis on accountability to 
stakeholders. 
The Regulation was intended to give Europe more confidence in the work of 
assessment, inspection and certification bodies. It made it possible to compare 
the results of different bodies and created a level playing field. The Regulation also 
facilitated trade through the “tested once, accepted everywhere” principle.
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The EA is the association of national accreditation bodies (NABs) within Europe. Members 
must be officially recognised by their national government. There are 36 full members 
and 12 associate members. EA members are required to participate in technical work 
and peer evaluations, and to use documents endorsed by the EA. 
The NABs signatories of the EA’s multilateral agreement (MLA) already recognise and 
accept the equivalence of accreditation systems operated by other signatories (even 
if they are different), and agree that they are equally reliable. EA members also share 
experience and expertise.
Using the accreditation legal framework in Europe has improved the harmonised 
application of standards, but challenges remain: accreditation services must still be 
developed for new markets and regulators. If no standard is available, accreditation 
cannot however be developed. Challenges concerning content and maintaining sufficient 
resources for peer evaluations also remain. 
2.4.2  The role of the accreditation legal framework in the 
European QA scheme (Silvia Deandrea, JRC & Aliki 
Stathopoulou, QASDG member)
The European QA scheme will incorporate accreditation processes related to the 
accreditation legal framework in two areas: 
1.  The certification bodies, certifying a breast centre under the European QA scheme,
will need to be accredited for this task by the national accreditation body according
to ISO standard 17065. The overall aim is to provide confidence to all interested
parties that all breast centres providing a certified service fulfil all specified requirements,
meaning that the certification service is standardised across the different certification
bodies providing it.
2.  Medical laboratory, pathology and imaging services related to a breast
centre wishing to obtain certification under the European QA scheme will need
to be accredited according to ISO 15189 or equivalent standards. This
standard is intended for medical laboratories and sets requirements for quality and
competence. It was developed with involvement from the medical, scientific and
clinical community. “The standard has been recognised by the International
Laboratory Accreditation Cooperation (ILAC) as the international standard
for the accreditation of medical laboratories worldwide,” said Stathopoulou.
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The use of ISO 17065 and ISO 15189 was approved following a call for feedback from 
country representatives. In the feedback, the vast majority of respondents consented 
to the use of ISO 17065, and 70 % consented to ISO 15189 (see the feedback report). 
Concerns expressed relate to the current use of alternative standards (the JRC is 
looking into using equivalence derogations within the scheme owner’s requirements), 
and applying a standard developed for medical laboratories to imaging services. Official 
responses to these issues will be published on the ECIBC web hub.
2.4.3  Experience with using ISO 15189 as an option for accrediting 
pathology laboratories (Marco Pradella, Local Health 
Authority Asolo, Italy)
In Italy, ISO 15189 has peculiarities, according to Pradella. To date, 113 testing labs, 
11 proficiency testing organisers, 6 medical labs and 1 reference medical lab have been 
accredited with this standard. No anatomic or pathology lab is yet accredited with it. 
Why are there so few accredited bodies in Italy? “It’s not because ISO doesn’t work,” said 
Pradella. There are three obstacles to taking up the internationally accepted 
ISO standard 15189:
1.  Interference with “institutional accreditation” (licensing) that is required by law.
The mandatory requirement for institutional accreditation, which may differ according
to the Italian region, results in organisations not considering additional accreditation
within the ISO system as feasible and useful.
2.  The use of ISO 9001 by many laboratories, which is considered to be an alternative
to ISO 15189, although it is not.
3.  A lack of investment in quality, due to cuts to the national health service budget
in the recent years.
The number of ISO 15189 accredited labs is however growing. For further growth, the 
country needs: 
1. government commitment;
2.  accreditation body regulations, procedures and modules that overcome regional barriers;
3.  empowerment of laboratory personnel. To increase the uptake of ISO 15189,
partnership with manufacturers (they can produce conformity evidence) and laboratory
empowerment are required.
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2.4.4  Experiences with implementing ISO 15189 (Katrien 
Gruenberg, Radboud University Medical Center (UMC), 
Nijmegen, the Netherlands)
In 2015, the pathology department at Radboud University Medical Center transitioned 
from a Dutch standard to ISO 15189. This decision was taken in March 2015, the request 
for accreditation was submitted in July 2015 and the audit carried out in December 
2015. Accreditation was awarded in 2016. The result was a rise in productivity and 
a decrease in costs.
The first thing the UMC did when preparing for accreditation was to install 
a quality management steering committee involving a chair, process coordinator, 
technician and pathologist. An advisor plus resident and incidents administrator were 
also involved.
The team then designed work processes (analysed workflow, described it, defined 
the critical steps, set indicators — and made it leaner along the way). This led to an 
organisation chart defining tasks and responsibilities; on the basis of this organisation 
chart, standard operating procedures were defined. 
In addition, quality management was put on the agenda of every relevant 
meeting, including the morning transfer meeting. 
The benefits of going through this process in preparation for the accreditation included 
the clarification of organisational factors (team leaders, no more work-arounds), 
processes (inefficiency reduced, problem solving easier), and learning more from things 
that do not go to plan. The disadvantage is the amount of work involved and the 
expense (fees, personnel). “But we think it pays off”, said Gruenberg.
The department now has very high operational efficiency. But accreditation applying ISO 
15189 does not per-se guarantee clinical effectiveness or a correct diagnosis. It was 
therefore decided to create a pathology review committee as a peer review instrument, and 
to set limited indicators, such as on speed (turnaround time), numbers, verifiability (number 
of revisions, percentage of (in)significant discordances). “This is a way to look into the mirror 
and see whether peers see you the same way you see yourself,” explained Gruenberg.
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3.  Day 2 – Policy for science
implementation
The ECIBC will only have an impact if its central tools — the European 
Breast Guidelines and European QA scheme — are taken up by countries and 
implemented within breast cancer services. The ECIBC’s European added value comes 
from its being based on evidence and respecting women’s rights to receive high-quality, 
evidence-based breast cancer care in Europe, across borders and regardless of the 
health system from which they are seeking treatment. Implementation of the European 
Breast Guidelines and the European QA scheme was discussed in three different formats: 
• individual country presentations, both as plenary presentations and during a
guided poster tour that took place during the first day;
• in a breakout session (country tables), where participants from the same country
grouped together and discussed facilitators and challenges to implementation;
• in a final round table discussion.
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3.1  Country presentations on Breast cancer services in 
European countries and the European QA scheme: country 
profiles (moderated by Tit Albrecht, National Institute of 
Public Health, Slovenia & Stefan Schreck, DG SANTE)
Schreck began by emphasising that responsibility for health remains with national 
ministries, but that the EU seeks to complement what the EU Member States 
are doing, where there is European added value. “If there is no European added value 
by doing something at European level, then we shouldn’t be doing it,” he said. Schreck 
also underlined DG SANTE’s commitment to the ECIBC. 
Tit Albrecht paid tribute to oncologist Umberto Veronesi, who recently passed away. 
He was one of the founders of the “Europe against cancer” programme; “we have to 
continue the legacy he started,” said Albrecht.
3.1.1 Scotland (Hillary Dobson, NHS Scotland)
Scotland receives financial allocations based on population and demographics for health 
care, but develops its health policy independently.
Scotland has a cancer action plan that is updated regularly and sets the direction 
for its strategy. How cancer will be managed is decided by health boards. The cancer 
quality framework works through three cancer networks, which have developed Quality 
Performance Indicators (QPIs), including for breast cancer. 
The cancer networks meet once a year to discuss what the data on QPIs shows about the 
services. To achieve this focus on quality, the NHS ensures accountability at the 
highest level. The CEOs of each health board were made responsible for developing action 
plans on quality improvement. An independent body assesses every three years whether the 
action plan is still appropriate. These assessments also lead to a list of recommendations for 
areas in which quality targets are deemed not to have been met, or quality has not improved. 
A data dashboard has been developed to present data at regional, unit or surgeon level. 
Quality measurement and improvement for each QPIs are reviewed regularly. The target 
standards were raised as a result of such a review as all centres were meeting them easily. 
QPIs were added for three additional areas, whereas two QPIs were archived as every unit was 
reaching the standard required and it was felt this had now become part of clinical practice.
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3.1.2  The Netherlands (Ruud Pijnappel, UMC Utrecht, on behalf 
of Sabine Siesling, University of Twente)
Incidences of breast cancer are rising in the Netherlands. Cases of invasive breast cancer, 
for example, rose from 8 000 in 1990 to 14 551 in 2015. The survival rate is however 
increasing. Some 77 % of patients diagnosed between 2004 and 2007 are still alive 
10 years later.
A national breast cancer screening programme was launched in 1990, initially for women 
aged 50-70, and since 1999 up to the age of 75. Women are invited for screening every 
two years. Mobile units ensure high attendance (around 80 %). 
The Netherlands also has a national breast cancer network (NABON, founded 
in 2011). The multidisciplinary group brings together clinicians, patients and 
health insurers. It has formulated three indicators for radiology, four for pathology, 
two for surgery and seven on waiting time. Once a year the indicators are sent to a 
transparency portal, which is open to health insurers. They are therefore able to 
see whether or not their contracted hospital is performing well.
Coupling the national pathology archive with the national cancer and national discharge 
registries provides a complete overview of diagnosis and time of death. 
Pijnappel reported challenges for implementing a European QA scheme, but spoke 
positively of the options it will open up, such as benchmarking against other countries 
and attaining international accreditation. To ease the burden of adapting, Pijnappel 
advised limiting the registration burden, attempting to fit the scheme within 
existing structures, making not all indicators compulsory, and maintaining 
a patient-oriented approach. 
3.1.3  Romania (Luciana Neamtiu, on behalf of Florian Nicula, 
Romanian programme for cancer prevention and control)
While breast cancer incidence in Romania is relatively low compared to the rest of the 
EU, mortality is comparatively high.
Population based screening does not exist, but was piloted with 5 000 women aged 
50-69 in 2014. 
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Oncology units exist in most major cities, and there is at least one in each of the 
42 Romanian counties. However, radiotherapy centres are scarce. 
The national accreditation body — RENAR — awards accreditation, but it is currently 
only used for medical laboratories, medical imaging and radiology. It is however in 
each hospital’s interests to be accredited as only those with accreditation receive 
funding from the national insurance house. 
Will it be possible to implement the European QA scheme in Romania? “I would say yes,” 
said Neamtiu. Certain hospitals are already using guidelines and protocols internally. 
Plus there is a quality management system, and an oncology cluster has been built up. 
Romania has all the services needed for the European QA scheme and now needs 
to work with the accreditation bodies to implement it. It will also be important 
to involve the national insurance house. “If it’s not involved, it won’t work,” said 
Neamtiu. Already willing to take the initiative forward, Neamtiu stated that the Oncology 
Institute “Prof Dr Ion Chiricuţă” will be able to pilot the European QA scheme, supported 
by the Ministry of Health.
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Guided poster tour
During the lunch break of day one, a guided tour of posters took place. Posters from 
nine European countries and from Bahrain were submitted. They all referred to the 
present system of care for breast cancer in the country depicted and addressed 
the implementation of the ECIBC in European countries:
•  Czech Republic, O. Ngo, O. Majek, J. Danes, P. Tesarova, Department of screening
programmes: Breast cancer care in the Czech Republic; ECIBC National Contact.
• Greece, N. Dimitropoulos, Athens University: Breast cancer care in Greece; on
behalf of the ECIBC National Contact.
•  Germany, S. Curelea, T. Beutler, DakkS: Accreditation activities in the field of
breast cancer; National Accreditation Body.
•  Hungary, D. Magdolna, D. Lajos, National Public Health and Medical Officer
Service (ÁNTSZ): Breast cancer care in Hungary; ECIBC National Contact.
•  Italy, A. Federici, Ministry for Health: Implementing the European QA scheme;
ECIBC National Contact.
•  Latvia, I. Engele, K. Arcimovica, M. Epermane, Riga East Clinical University Hospital: 
The nationwide mammography screening programme in Latvia – Implementing
the European QA scheme; ECIBC National Contact.
•  Norway, P. Andersen, Norwegian Directorate of Health: Breast cancer care
in Norway; on behalf of the ECIBC National Contact.
• Slovakia, K. Pohlodek, A. Kállayová, M Ondrušová, J. Slobodníková, University
Hospital of Bratislava: Breast cancer screening in Slovakia; ECIBC National
Contact.
•  Switzerland, A. Kässner, Federal Office of Public Health: The characteristics of
breast cancer care in Switzerland; on behalf of the ECIBC National Contact.
•  Turkey, M. M. Kurt Soykan, D. Kiziltan, Turkak: Breast cancer care characteristics
in Turkey; on behalf of the ECIBC National Contact.
•  Bahrain, Z. Fedorowicz, J. Sprakel, T. Al Alawa, Cochrane Bahrain: A breast cancer
clinical guideline for the Kingdom of Bahrain.
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3.2 Country tables (Donata Lerda, JRC)
Discussing the feasibility of ECIBC implementation in European countries
“It’s your turn to tell us what you need. There is no impact without 
implementation,” said Lerda as she introduced the country tables session and 
expected outcomes. Representatives from national health authorities and 
stakeholders joined European Breast Guidelines and European QA scheme group 
members around country tables.
A total of 15 tables were set up, of which 8 brought together representatives from more 
than one country. Out of the 35 countries participating in the ECIBC, 27 were represented. 
Each table received factsheets presenting their country’s responses to the past open calls for 
feedback on the scope of the European Breast Guidelines and the European QA scheme, and 
each country was asked to fill in a short questionnaire on ECIBC implementation opportunities.
Country table outcomes where expected to provide the basis for the roundtable discussion 
that followed. The outcomes were therefore summarised and presented at the end of 
the breakout by Lerda.
After lively discussions at each table, a questionnaire was received from all participating 
countries. All contained responses on both the European Breast Guidelines and the 
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European QA scheme. The majority of countries also provided information on additional 
national contacts to be approached by the JRC in preparation for implementation.
3.2.1 European Breast Guidelines
Some 25 countries out of the 27 present reported either having a screening 
programme or being in the process of rolling one out. All 25 complied with the 
European Breast Guidelines recommendations, having a screening programme at 
least for the age group 50 to 69. 
For those countries reporting issues with the ECIBC recommendations, most related to 
the age range 45-49.
Comments collected from the questionnaires called for more awareness-raising 
of the recommendations and more discussion on screening for women aged 
70-74 years. Comments also noted current alignment with the recommendations. 
In general, the questionnaires showed the recommendations were viewed as a 
useful basis for a dialogue with policy makers on the necessity of population-based 
screening programmes and the ages to be prioritised. 
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3.2.2 European QA scheme
All but one of the 27 countries reported a national/regional policy for the 
organisation of breast cancer care. The modules proposed by the European QA 
scheme were deemed appropriate for 24 out of 27 countries. Two reported concerns 
about the end-of-life care module. The option to compare quality of breast cancer 
care between EU countries with the help of the European QA scheme was 
appreciated by most respondents.
The responses showed that the accreditation infrastructure foreseen is not yet fully 
understood by all, while seven questionnaires expressed doubts about the readiness 
of their country’s accreditation structure to adopt this part of the scheme. The JRC 
offered to sit with representatives from each individual country and clarify 
the specific issues in relation to implementation and how they could be solved. Lerda 
offered reassurance that the European QA scheme aims to be as flexible as possible 
to find solutions tailored to each country’s needs. A dialogue with one national 
accreditation body has already led to an agreement on a more flexible structure for 
accreditation requirements. One country table welcomed a QA scheme that would 
reassure breast cancer services that “the efforts that they are taking are indeed going 
in the right direction”.  
Lerda described the country table exercise as very successful in providing extremely 
useful information about the (potential) impact of the ECIBC on national health policies. 
The material that the JRC received through the call for feedback on the scope of the 
European QA scheme  and through the country tables will help to deepen understanding 
of implementation opportunities for the ECIBC in different countries. This knowledge will 
be further expanded over the next two years, during which time the JRC will also seek a 
direct exchange with individual countries.
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3.3 Round table discussion
What needs to be done at European and national levels to implement the 
European QA scheme? (moderated by Ciarán Nicholl, JRC)
Participants: Roswitha Britz, Europa Donna President 1; Zofija Mazej Kukovič, Slovenian 
policy maker; Alojz Peterle, President of “MEPs Against Cancer” (MACs), European 
Parliament; Iveta Nagyova, EUPHA; Birgit Beger, ECCO; Stefan Schreck, DG SANTE; Elke 
Anklam, JRC
Nicholl reassured participants that the JRC will be approaching each country to ensure 
that the ECIBC initiatives will not have a negative impact on existing health schemes. 
“That would be counter-productive,” he said. “We are committed to the Member States, 
that’s the function of the EU.”
In response to appeals for flexibility, MEP Alojz Peterle (president of “MEPs Against 
Cancer” (MACs)) said, “There are areas where we can be very flexible, and areas 
where we can’t be” if we are to ensure the highest quality of care for patients. 
He also called for political promotion of the European QA scheme. 
1 Roswitha Britz’s speech can be found here 
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Other comments from the floor addressed a need for additional information on the 
benefits of the accreditation proposed by the ECIBC, and the prior existence of well-
implemented screening programmes and QA schemes in certain countries that are 
tailored to each country’s individual circumstances.
Stefan Schreck of DG SANTE also reminded participants that the recommendations are 
not law. “Follow or don’t follow if something doesn’t apply to your circumstances. But if 
you do something other than what is recommended in the guidelines, please 
explain why.”
To support from elsewhere in the audience, one participant requested that the JRC 
contacts ministries directly as they do not always listen to experts: “They have to 
understand why changes are necessary, and you have the evidence.”
Zofija Mazej Kukovič called for a change in “mind set” towards common standards 
for quality in breast cancer care. Implementing common standards among EU Member 
States has been done before in other policy fields. In the beginning such a process is 
always associated with much effort: ‘There will be lot of administration, and people 
will say this is typical of EU’. But once standards are implemented the administrative 
effort will become less and the benefits will be appreciated. “Everything will be more 
transparent, and patients will for sure have greater trust in the system.”
The discussion turned to the question of continuity of care, with one participant 
highlighting that as the European QA scheme will be modular, and certification can be 
attained step-by-step, it remains a challenge to guarantee that quality of care is 
assured across the interfaces of care modules and care responsibilities. “It will 
be a long-term aspiration to join up these different modules, however in the end this is 
what counts for the patient.”
Discussions also covered who has the authority to ensure implementation of the screening 
recommendations, and how efficient it would be to target ministers; they may change 
frequently, and with each new minster lobbying must start again from scratch. Instead 
of ministers it might be more useful to approach screening programme managers, some 
suggested. It is likely that the level of policy maker to approach when lobbying for 
implementation will vary from country to country. The JRC concluded that it needs 
to develop a communication and dissemination strategy for ECICB output. 
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Peterle provided words of reassurance and proposed to include health issues in the 
European semester, “which at the moment is limited to economic issues. This would lead 
to more continuity.”
Schreck reassured the Plenary that the JRC and DG SANTE would talk to everyone 
relevant, including ministers, high-, mid- and low-level officials and chief medical officers.
Round table participant Nagyova advocated activating public health and patient 
organisations who can take a bottom-up approach to lobbying for change. Other 
targets for lobbying include the directors of national cancer plans.
The roundtable discussion finished with a reminder that the tools that the ECIBC is 
developing will be watched and absorbed by countries outside Europe as well as 
within. Francesco Sardanelli, vice chair of QASDG marked from the audience that there 
needs to be an awareness that, “from the point of view of other countries for 
example in Latin America, Africa and others, Europe is a role model”. 
3.4  Conclusions (Alojz Peterle, President of MEPs Against 
Cancer (MACs), European Parliament)
Peterle, who is a cancer survivor himself and knows the JRC 
and its work well, declared the Plenary’s two rainy days as 
sunny days. “Science and policy met – this has to happen.” 
He welcomed the inclusive nature of the gathering, marking 
it out as a European initiative. 
Looking ahead, to ensure continuation of the important 
work begun, Peterle called for proactive sharing of the 
relevance of the European Breast Guidelines and European QA scheme, as well 
as efforts to ensure an even more favourable political context. “We can do more at all 
levels. Let’s continue the good work,” he said, closing the 2016 Plenary.
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4. Evaluation
About one fifth of the 150 participants responded to a survey evaluating the event. 
Evaluation was carried out online and reminders were sent. Those who responded 
confirmed that the Plenary’s aim — to inform stakeholders — was met:  all respondents 
felt that the event succeeded in providing a comprehensive overview of how 
the ECIBC is progressing, and what the challenges are (see figure 1). 
On the organisation of the event, respondents’ expectations were overwhelmingly met 
or exceeded in terms of the speakers and the balance of the sessions, while feedback on 
the logistics was equally positive, with expectations frequently surpassed for location, 
communication and the time allocated to networking. 
The section of the Plenary devoted to ECIBC news and updates received overwhelmingly 
positive reviews, which was also the case for all other Plenary sessions on the first day. 
Some however thought that more time for discussion would have been helpful: “I miss 
the discussion between the participants and the project team. It is good to have some 
overview of the projects. The value should be the input of the experts during discussion.” 
The country tables were viewed positively. While some participants would have preferred to 
see more time allocated to this session, in particular for interaction with other participants, 
many survey respondents highlighted the relevance of the country tables for them: “I am 
an accreditation person, so for me it was very useful to see the other side.”
Other survey comments highlighted increased motivation following the event to further 
advance evidence-based breast cancer care in their country, and the wish for further 
exchange and collaboration: “For a country like … and for me as the coordinator for the 
breast cancer screening program, this was a very important meeting. Perfectly organized 
and perfect speakers, also many nice people. Now, staying in contact and following the 
ECIBC is the next important step.”
Figure 1:  The ECIBC Plenary rated for “clearly 
outlining the current state of the 
development and challenges of the 
ECIBC”.
O
8
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5. Conclusions
The 2016 ECIBC Plenary was an overall success in meeting the mandate and 
expectations of participants and organisers alike. As the evaluation of the event 
revealed, participants felt well informed in terms of the development of ECIBC tools, and 
in particular the European Breast Guidelines and the European QA scheme. 
The launch of the first four guidelines recommendations, which are based entirely on 
the latest evidence, not only marked an important milestone in the progression of 
the ECIBC, but moreover in the progression of Europe’s approach to clinical guidelines 
in general. For both, the guidelines and the QA scheme, the clinical experience of 
experts, together with the evidence, is being translated into relevant recommendations 
and requirements that should ultimately result in improved quality of breast cancer 
care. And during the entire process, the ECIBC keeps the patient at the centre of all 
deliberations.
Placing the focus on individual countries on the second day, and in particular on 
encouraging stakeholders from the same country to talk to one another about the 
options for implementing the European Breast Guidelines and the European QA scheme 
proved valuable. The lively discussion not only provided valuable information to the JRC, 
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helping to clarify issues, but also created a momentum which will hopefully spill over 
as countries begin preparing for implementation. It was reassuring for the Commission 
to see the extent to which the guidelines recommendations were welcomed as a basis 
for policy discussion on breast cancer at national level, and to see that some of the 
recommendations are already de facto in place or are at the policy uptake stage.
What happens next? While the 2016 ECIBC Plenary sought to prepare the ground for the 
implementation of both the guidelines and the QA scheme, the next Plenary will see the 
presentation of the European Breast Guidelines and the European QA scheme as they 
approach finalisation. The ensuing fourth ECIBC Plenary will present results from the first 
implementation phase of the European QA scheme; the pilot implementation will take 
place in breast cancer services across Europe, which represent the different contexts in 
EU Member States and within health systems. Discussing experiences of the pilot phase 
within the Plenary will help to adjust the tools so that they are ready for implementation. 
The pilot is scheduled for 2018, but country representatives and other 
stakeholders will be asked to contribute before then. Before the European QA 
scheme is piloted, they will receive a final set of requirements with a request for feedback 
and their approval of the feasibility of technical implementation. They will also be invited 
to get into direct exchange with the JRC on implementation. 
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6. Annexes
Agenda
Day 1: Science for Policy Development
09:30-10:10 Welcome & Opening
• Welcome note
Charlina Vitcheva, JRC
• The patient’s perspective on ECIBC
Marja Aarnipuro, Apu magazine, Finland
•  Launch of the first set of European Breast Guidelines
recommendations
Elke Anklam, JRC
10:10-10:15 Presentation of the agenda
Donata Lerda, JRC
10:15-11:00 What kind of science is successful in supporting policy development– 
the scientists perspective
Josep Figueras, European Observatory on Health Systems & Policies
11:00-11:30 Coffee
11:30-13:00 News and update from the ECIBC projects 
Moderated by Elke Anklam, JRC and Zofija Mazej Kukovič, , 
Slovenian policy maker 
• Session introduction
Zofija Mazej Kukovič, , Slovenian policy maker
•  Status of the development of the European quality assurance
scheme for breast cancer services
Robert Mansel, QASDG chair
•  Status of the development of the European guidelines for breast
cancer screening and diagnosis
Chris de Wolf, GDG co-chair and Holger Schünemann, GDG co-chair 
• Status of the development of the Guidelines Platform
Donata Lerda, JRC
13:00-14:30 Walking lunch and Guided poster tour  
Moderated by Anke Bramesfeld, Silvia Deandrea, JRC
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14:30-15:00 Continued: News and update from the ECIBC projects 
Moderated by Elke Anklam, JRC and Zofija Mazej Kukovič, 
Slovenian policy maker
•  Training on digital mammography: a European approach
Aslı Ulutürk, JRC
• Monitoring the impact of ECIBC
Nadya Dimitrova, JRC
• Presentation of ECIBC video
Elke Anklam, JRC
15:00-16:00 Making comparable performance assessment possible in Europe 
by using the accreditation legal framework
Moderated by Jane Beaumont, Accreditation Adviser, and M 
arc van den Bulcke, Scientific Institute of Public Health, Brussels
•  What is the accreditation legal framework, what are its benefits
and shortcomings
Ed Wieles, Dutch Accreditation Council, The Netherlands
•  The role of the accreditation legal framework in the European QA
scheme
Silvia Deandrea, JRC and Aliki Stathopoulou, QASDG member
16:00-16:30 Coffee
16:30-17:30 Experience with using ISO 15189 as an option for accrediting 
pathology   laboratories
Marco Pradella, Local Health Authority Asolo, Italy
•  Experiences with implementing ISO 15189
Katrien Grünberg, Radboud University Medical Center,
Nijmegen, The Netherlands
19:00 Gala dinner at Villa Panza, Varese
Bus transport to/from hotels.
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Day 2: Policy for science Implementation
09:30-10:45 Break out session
Discussing feasibility of implementation of the European QA scheme 
in different European Countries
• Introduction
Donata Lerda, JRC
• Coffee + Country tables
National accreditation bodies, ECIBC National Contacts and stake-
holders meet at their own national coffee table to discuss the 
possible implementation of the European QA scheme in their country
10:45-11:30 Breast cancer services in European countries and the European 
QA scheme: country profile
Moderated by Tit Albreht, National Institute of Public Health, 
Slovenia and Stefan Schreck, DG SANTE
• Scotland
Hillary Dobson, NHS Scotland
• The Netherlands
Sabine Siesling, University of Twente
• Romania
Florian Nicula, Romanian programme for cancer prevention and control
11:30-11:35 Presentation of ECIBC video
Ciarán Nicholl, JRC
11:35-11:45 Debriefing Country tables
Donata Lerda, JRC
11:45-12:45 Round table discussion
What needs to be done at European and national levels 
to implement the European QA scheme
Moderated by Ciarán Nicholl, JRC
Elke Anklam, JRC
Simona Bonafè,* Member of the European Parliament
Roswitha Britz, President of Europa Donna
Nessa Childers,* Member of the European Parliament
Miriam Dalli,* Member of the European Parliament
Alojz Peterle, President of the MEPs Against Cancer (MACs), 
European Parliament
Charlina Vitcheva, JRC
12:45-13:00 Conclusions
Alojz Peterle, President of the MEPs Against Cancer (MACs), 
European Parliament
13:00 Lunch
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Participants
List of speakers, including CVs can be found in the plenary booklet
Marja AARNIPURO Apu magazine / A-lehdet Oy Finland
Tit ALBREHT National Institute of Public Health Slovenia
Pablo ALONSO Iberoamerican Cochrane Centre Spain
Per Kr. ANDERSEN Norwegian Directorate of Health Norway
Elisabeth ANDRITSCH International Society of Psycho-Oncology Canada
Kathi APOSTOLIDIS ECPC European Cancer Patient Coalition Belgium
Krista ARCIMOVICA Riga East University Hospital Latvia
Myrto AZINA-CHRONIDES Ministry of Health Cyprus
Mónica BALLESTEROS Iberoamerican Cochrane Centre Spain
Partha BASU International Agency for Research on Cancer France
Jane BEAUMONT Accreditation Advice United Kingdom
Birgit BEGER European CanCer Organisation (ECCO) Belgium
Karen BENN Europa Donna The European Breast Cancer Coalition Italy
Elizabeth BENNS Independent Cancer Patients' Voice United Kingdom
Elizabeth BERGSTEN 
NORDSTRÖM
Swedish Breast Cancer Association Sweden
Gunita BERKE Europa Donna Latvia/Latvian Cancer Patients 
Association " Dzivibas koks" 
Latvia
Jacques BERNIER Genolier Swiss Medical Network Switzerland
Thomas BEUTLER Deutsche Akkreditierungsstelle GmbH 
(German Accreditation Body)
Germany
Magdalena BIELSKA-LASOTA National Institute of Public Health - National 
Institute of Hygiene 
Poland
Christian BOEHLER Independent consultant Austria
Hanno BOHL Estonian Cancer Society Estonia
Bettina BORISCH Université de Genève Switzerland
Andrew BOTTOMLEY EORTC Belgium
Julia BOYSEN Stadtspital Triemli Switzerland
Marco BRAMBILLA European Federation of Organisations for Medical 
Physics
Italy
Roswitha BRITZ Europa Donna Spain
Mireille BROEDERS Dutch Reference Centre for Screening Netherlands
Inga BROKERE National Health Service Latvia
Sara BRUCKER Research Centre for Women's Health at Tübingen 
University
Germany
Jean-Luc BULLIARD Lausanne University Hospital- Faculty of Biology 
and Medicine
Switzerland
Marie CANTWELL Queen's University Belfast United Kingdom
Flavia CARDINALI Agenzia Nazionale per i Servizi Sanitari Regionali Italy
Francesca CAROZZI Institut of Cancer Prevention ISPO Italy
Antonino CARTABELLOTTA Fondazione GIMBE Italy
Paloma CASADO Ministry of health social services and equality. Spain. Spain
Isabella CASTELLANO University of Turin Italy
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Xavier CASTELLS Hospital del Mar de Barcelona Spain
Luigi CATALIOTTI Breast Centres Certification Italy
Saskia CLAASSEN Catharina Hospital Netherlands
Sue COHEN Public Health England United Kingdom
Edoardo COLZANI European Centre for Disease Prevention and Control 
(ECDC)
Sweden
Mike CORNBLEET Healthcare Improvement Scotland United Kingdom
Massimo CORSARO Pfizer Italy
Simona CURELEA DAkkS (German Accreditation Body) Germany
Jan DANEŠ Charles University in Prague- First Faculty of Medicine Czech Republic
Magdolna DANK MD Semmelweis Egyetem Onkologiai Kozpont Hungary
Nynke DE JONG National Institute for Public Health and the 
Environment
Netherlands
Isabel DE LA VILLA ENAC Spain
Christophorus DE WOLF ADSAN Switzerland
Maria Victoria DE ZABALA Europa Donna Belgium Belgium
Nikolaos DIMITROPOULOS DELTA DIGITAL SA Greece
Hilary DOBSON NHS SCOTLAND United Kingdom
Stephen DUFFY Queen Mary University of London United Kingdom
Adrie DUMAIJ National Institute for Public Health and the 
Environment
Netherlands
Maie EGIPT Estonian Cancer Society Estonia
Miriam ELFSTRÖM Regional Cancer Center of Stockholm-Gotland- 
Stockholm County Council
Sweden
Ilze ENGELE Riga Eastern University hospital Latvia
Josep A ESPINAS Catalan Cancer Plan Spain
Antonio FEDERICI Ministero della salute, Dipartimento di prevenzione Italy
Zbys FEDOROWICZ Cochrane BAHRAIN Bahrain
Maria Conceicao FERREIRA Pfizer GmbH Germany
Rosanna FIDANZIA Europa Donna Italia Italy
Josep FIGUERAS European Observatory on Health Systems and Policies Belgium
Markus FOLLMANN German Cancer Society Germany
Claudio GALLI Abbott Diagnostics Italy
Cristina GARCIA VIVAR European Federation of Nurses Associations (EFN) Belgium
Franco GATTAFONI ACCREDIA Italy
Sija GEERS- VAN GEMEREN European Federation of Radiographer Societies Netherlands
Daniele GENERALI Azienda Socio Sanitaria Territoriale (ASST) di Cremona Italy
Alessandra GENNARI E.O.Galliera Italy
Livia GIORDANO Azienda Ospedaliera Citta della Salute e della 
Scienza di Torino
Italy
Paolo GIORGI ROSSI AUSL Reggio Emilia Italy
Jola GORE-BOOTH EuropaColon Ltd United Kingdom
Urska GRAHEK Joint Research Centre Belgium
Axel GRÄWINGHOLT Self employed Germany
Andre GRIVEGNEE INSTITUT JULES BORDET Belgium
Katrien GRUNBERG Radboud University Medical Center Netherlands
Freja HAGSUND European Regional and Local Health Authorities 
(EUREGHA)
Belgium
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Stephen HALLORAN NHS Bowel Cancer Screening Programme United Kingdom
Sirpa HEINAVAARA Cancer Society of Finland / Finnish Cancer Registry Finland
Belinda HENSHAW Healthcare Improvement Scotland United Kingdom
Solveig HOFVIND Norwegian Breast Cancer Screening Program Norway
Christopher HOLCOMBE NHS in England United Kingdom
Svetlana JIDKOVA Center for cancer detection Belgium
Henrik 
Lykkegaard
JØRGENSEN DANAK Denmark
Anja KAESSNER Federal Office of Public Health Switzerland
Damla KIZILTAN Turkish Accreditation Agengy Turkey
Thanos KOSMIDIS Care Across United Kingdom
Tibor KOVACS European Society of Surgical Oncology Belgium
Merve Meltem KURT SOYKAN TURKISH ACCREDITATION AGENCY Turkey
Viola KUTAS National Accreditation Authority Hungary
Miranda LANGENDAM Academic Medical Center / University of Amsterdam Netherlands
Zbigniew LES Evidence Prime Poland
Jesus LÓPEZ ALCALDE Cochrane Madrid Spain
Anne MACKIE Public Health England United Kingdom
Robert MANSEL EUSOMA United Kingdom
Lorenza MAROTTI EUSOMA Italy
Zofija MAZEJ KUKOVIC Former Member of European Parliament Slovenia
Helen MCGARRIGLE Cardiff and Vale Breast Unit United Kingdom
Ana MOLINA Fundación para el Fomento de la Investigación 
Sanitaria y Biomédica (FISABIO)
Spain
Lydia MOUZAKA Hellenic Senologic Society Greece
Iveta NAGYOVA European Public Health Association - EUPHA Netherlands
Peter NAREDI ECCO Belgium
Luciana NEAMTIU Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca Romania
Eva NEGRI Istituto di Ricerche Farmacologiche Mario Negri Italy
Ondrej NGO Institute of Biostatistics and Analyses- Masaryk 
University
Czech Republic
Lennarth NYSTRÖM Umeå University Sweden
Ruben ORDA SIS/ISS (SENOLOGIC INTERNATIONAL SOCIETY/
INTERNATIONAL SCHOOL OF SENOLOGY
Israel
Eugenio PACI formerly  ISPO Cancer Research and Prevention 
Institute - Florence (retired)
Italy
Elsa PEREZ University Hospital Dr. Josep Trueta Spain
Elena PÉREZ SANZ Dirección General de Salut Pública de Comunitat 
Valenciana
Spain
Alojz PETERLE European Parliament Belgium
Niall PHELAN BreastCheck Ireland
Ruud PIJNAPPEL Dutch Reference Center for Screening Netherlands
Kamil POHLODEK Comenius University of Bratislava- Faculty 
of Medicine- Bratislava- Slovakia
Slovakia
Marco PRADELLA ULSS 8 Asolo Italy
Liisa PYLKKANEN Cancer Society of Finland Finland
Daniela QUAGGIA Cittadinanzattiva - Active Citizenship Network Italy
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Ulla RAID Health System Development Department – Ministry 
of Social Affairs
Estonia
Alexandra RAMSSL-SAUER Gesundheit Österreich GmbH Austria
Vitor RODRIGUES Faculdade de Medicina - Universidade de Coimbra Portugal
Dolores SALAS Direccion General Salud Pública Valencia 
Community- FISABIO 
Spain
Anna SAPINO Institute of Cancer Research Italy
Francesco SARDANELLI University of Milan- Research Hospital Polilcinico 
San Donato
Italy
Holger SCHUNEMANN McMaster University Canada
Elisabetta SESTINI Europa Donna Italia Italy
Sabine SIESLING Comphrehensive Cancer Centre the Netherlands 
(IKNL
Netherlands
Christian SINGER Medical University Vienna Austria
Julie SPRAKEL Bahrain Breast cancer Society- Think Pink Bahrain Bahrain
Aliki STATHOPOULOU HELLENIC ACCREDITATION SYSTEM - ESYD Greece
Svetlana TEMELKOVSKA University Clinic of radiology Skopje the former 
Yugoslav 
Republic of 
Macedonia
Luzia TRAVADO Champalimaud Clinical Centre- Champalimaud 
Foundation
Portugal
Francisco TRESSERRA HOSPITAL UNIVERSITARIO DEXEUS Spain
Martin UNDERWOOD Warwick Clinical Trials Unit United Kingdom
Marc VAN DEN BULCKE Scientific Institute of Public Health Belgium
Cary VAN LANDSVELD-
VERHOEVEN
LRCB | Dutch Reference Centre for Screening Netherlands
Chantal VAN ONGEVAL University Hospitals Leuven Belgium
Elke VAN ROSSEN BELAC Belgium
Elizabeth VERSCHUUR-VAN DER 
VOORT
Dutch Breast Cancer Society Netherlands
Charlina VITCHEVA Joint Research Centre Belgium
Sue WARMAN Independent United Kingdom
Elisabete WEIDERPASS VAINIO Cancer Registry of Norway - -Institute of Population 
Based Cancer Research
Norway
Ed WIELES Dutch Accreditation Council RvA Netherlands
Margaret WILCOX Independent Cancer Patients Voice United Kingdom
Mary WOODS The Royal Marsden NHS Foundation Trust United Kingdom
Stephanie XUEREB National Screening Programmes- Ministry of Health Malta
Wendy YARED European Cancer Leagues (ECL) Belgium
Kenneth YOUNG Royal Surrey County Hospital United Kingdom
Marco ZAPPA ISPO  Italy
Janez ŽGAJNAR Institute of Oncology Ljubljana Slovenia
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References
Additional ECIBC documents and publications are available online.
Council of the European 
Union"s conclusions on 
reducing the burden  
of cancer
http://eur-lex.europa.eu/legal-content/EN/TXT/
PDF/?uri=CELEX:52014DC0584&from=en 
recommendations http://ecibc.jrc.ec.europa.eu/recommendations/
methodology document http://ecibc.jrc.ec.europa.eu/qa-methodology
video http://ecibc.jrc.ec.europa.eu/ecibc-for-you
Feedback report
https://bookshop.europa.eu/en/report-on-the-call-for-
feedback-about-the-scope-of-the-european-quality-
assurance-scheme-for-breast-cancer-services-
pbLANA28188/
Booklet http://ecibc.jrc.ec.europa.eu/-/ecibc-plenary-2016
ECIBC reports http://ecibc.jrc.ec.europa.eu/reports
ECIBC documents http://ecibc.jrc.ec.europa.eu/other-documents
Roswitha Britz http://europa.eu/!Xw34Kb
GETTING IN TOUCH WITH THE EU 
In person 
All over the European Union there are hundreds of Europe Direct information centres. You can find the 
address of the centre nearest you at: http://europea.eu/contact 
On the phone or by email 
Europe Direct is a service that answers your questions about the European Union. You can contact this 
service: 
- by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls), 
- at the following standard number: +32 22999696, or 
- by electronic mail via: http://europa.eu/contact 
FINDING INFORMATION ABOUT THE EU 
Online 
Information about the European Union in all the official languages of the EU is available on the Europa 
website at: http://europa.eu 
EU publications 
You can download or order free and priced EU publications from EU Bookshop at: 
http://bookshop.europa.eu. Multiple copies of free publications may be obtained by contacting Europe 
Direct or your local information centre (see http://europa.eu/contact). 
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